Thera-SAbDab

ROZIPAFUSP

> Structural Summary

Therapeutic	Rozipafusp
Target	ICOS
Heavy Chain	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS
Light Chain	DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK
100% seqID Fv Structure	6x4t [Fvs: BE, DF]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	6x4t [Fvs: BE, DF]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb Fusion
Isotype	G2
Highest Clinical Trial (June '19)	Phase-I
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2018
INN Year Recommended	None
Companies Involved	Amgen
Conditions Approved	na
Conditions Active	Rheumatoid arthritis
Conditions Discontinued	Systemic lupus erythematosus
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]